Associations Between Inflammation and Cognitive Function in African Americans and European Americans by Windham, B. Gwen et al.
Associations Between Inflammation and Cognitive Function in
African Americans and European Americans
B. Gwen Windham, MD, MHS,*1 Brittany N. Simpson, BA,†1 Seth Lirette, MS,‡ John Bridges, MS,†
Lawrence Bielak, DDS, MPH,§ Patricia A. Peyser, PhD,§ Iftikhar Kullo, MD,¶ Stephen Turner, MD,¶
Michael E. Griswold, PhD,‡ and Thomas H. Mosley, PhD*
OBJECTIVES: To examine associations between specific
inflammatory biomarkers and cognitive function in African
Americans (AAs) and European Americans (EAs) with pre-
valent vascular risk factors.
DESIGN: Cross-sectional analysis using generalized esti-
mating equations to account for familial clustering; stan-
dardized b-coefficients, adjusted for age, sex, and
education are reported.
SETTING: Community cohort study in Jackson, Missis-
sippi, and Rochester, Minnesota.
PARTICIPANTS: Genetic Epidemiology Network of Arte-
riopathy (GENOA)–Genetics of Microangiopathic Brain
Injury (GMBI) Study participants.
MEASUREMENTS: Associations between inflammation
(high-sensitivity C-reactive protein (CRP), interleukin
(IL)-6, soluble tumor necrosis factor (TNF) receptor 1 and
2 (sTNFR1, sTNFR2)) and cognitive function (global, pro-
cessing speed, language, memory, and executive function)
were examined in AAs and EAs (N = 1,965; aged 26–95,
64% women, 52% AA, 75% with hypertension).
RESULTS: In AAs, higher sTNFR2 was associated with
poorer cognition in all domains (global: 0.11, P = .009;
processing speed: 0.11, P < .001; language: 0.08,
P = .002; memory: 0.09, P = .008; executive function:
0.07, P = .03); sTNFR1 was associated with slower pro-
cessing speed (0.08, P < .001) and poorer executive func-
tion (0.08, P = .008); higher CRP was associated with
slower processing speed (0.04, P = .024), and higher IL6
was associated with poorer executive function (0.07,
P = .02). In EA, only higher sTNFR1 was associated with
slower processing speed (0.05, P = .007). Associations
were not found between cognition and sTNFR2, CRP, or
IL6 in EA.
CONCLUSION: In a population with high vascular risk,
adverse associations between inflammation and cognitive
function were especially apparent in AAs, primarily involv-
ing markers of TNFa activity. J Am Geriatr Soc 62:2303–
2310, 2014.
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Dementia affects approximately 5 million people in theUnited States, with Alzheimer’s disease (AD) account-
ing for 60% to 80% of these cases and vascular cognitive
impairment accounting for most of the remainder. Vascu-
lar disease causes cognitive impairment and amplifies the
deleterious effects of AD pathology by lowering the thresh-
old for cognitive impairment and augmenting the trajec-
tory of cognitive decline.1–3 Growing evidence suggests
that inflammation may contribute to the pathophysiology
of AD and vascular dementia (VaD).4 Furthermore, studies
demonstrating that adding inflammatory markers to the
model improves predictive ability of lipid markers in car-
diovascular disease outcomes5 provide face validity for an
inflammatory-mediated role in vascular disease of the
brain, similar to that of other end organs.
Associations between cognitive function and interleu-
kin-6 (IL6),6–9 tumor necrosis factor (TNF)-a and soluble
TNF receptors (sTNFRs),10–12 and C-reactive protein
(CRP)8, 3–17 have been reported. Inflammation may be
involved differently in VaD and AD and in different racial
and ethnic groups. For example, TNFa,18 CRP, and IL615 are
higher in persons with VaD than in those with AD and may
be important risk factors for cognitive impairment in persons
with cardiovascular risk factors. Although African Ameri-
cans (AAs) may be more likely to have dementia than Euro-
pean Americans (EAs),19 few studies of inflammation and
cognitive function have included AAs.6,7,13 Inflammatory bi-
omarker levels appear to differ between AAs and EAs20–22
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and AAs may have stronger responses to inflammatory stim-
uli than EAs.23 In addition, some20,21,24,25 but not all stud-
ies26 suggest that levels and actions of inflammatory markers
differ in EAs and AAs and may contribute differently to the
pathophysiology of dementia. The purpose of this study
was to examine associations between CRP, IL6, and TNFa
activity and cognitive function in EAs and AAs with pre-
valent cardiovascular risk factors, all of whom had hyper-
tension or two siblings with hypertension before age 60.
METHODS
Population
The Genetic Network of Arteriopathy (GENOA) study,
begun in 1995, follows a well-characterized cohort of indi-
viduals with hypertension and their siblings recruited from
Jackson, Mississippi (AA only) and Rochester, Minnesota
(EA only) (N = 3,437; 66% female, 57% AA, aged 28–91,
52% obese at baseline). At least two members of each sib-
ship had hypertension before age 60 at enrollment. Inflam-
matory markers were assayed at the second examination
(GENOA Visit 2, 2000–04). Neurocognitive testing was
conducted at or after Visit 2 (The Genetics of Microangio-
pathic Brain Injury [GMBI], 2001–06; hereafter included
with Visit 2). Participants in Visit 2 and GMBI (n = 2,721)
included 1,239 individual EAs (469 full-sibling pairs) and
1,482 individual AAs (626 full-sibling pairs). Of these, 162
(3 EA, 159 AA) were missing information on all inflamma-
tory markers, and 10 self-reported a history of dementia
and were excluded, leaving 2,549 participants. Cognitive
data were available for 1,965 (960 EA, 1,005 AA), who
constitute the analysis dataset, including those in the data-
set for the sensitivity analyses, which addresses potential
bias of missing data. Of these, 1,857 (95%) had inflamma-
tory biomarker data and constitute the completers data set.
Inflammatory Markers
At Visit 2, fasting blood samples were centrifuged for
10 minutes at 4°C, aliquoted in 0.5- to 1-mL volumes of
ethylenediaminetetraacetic acid plasma (serum for CRP),
and stored at 80°C within 2 hours of venipuncture; frozen
samples were shipped to the Mayo Clinic Immunochemical
Core Laboratory (Rochester, MN) overnight on dry ice.
CRP assays were performed using immunoturbidometric
assays (Diasorin, Inc., Stillwater, MN; interassay impreci-
sion 1.8–2.6%; intraassay imprecision 1.0–9.2%), and mul-
tiplex assays (SearchLight, Pierce, Boston, MA) were used
for IL-6 and sTNFRs; sTNFR fractions show stability over
time, with longer half-lives than TNFa levels, and have
been validated as sensitive indicators of TNF-a system acti-
vation.27,28 Precision of the assays performed using Search-
Light was retrospectively determined based on data derived
from a blinded internal plasma control sample. Algorithms
were developed to reduce plate-to-plate variations in pro-
tein levels, and all analyses used these normalized data.29
Cognitive Testing
Neurocognitive tests were offered to all participants in the
same sequence using standardized protocols to assess
global mental status, memory, language, processing speed,
and executive function. All scores were ordered so
that higher values reflect better cognition, and standard-
ized coefficients were used to allow comparisons across
measures.
Global Cognitive Function
The Mini-Mental State Examination (MMSE, range 0
[worst] to 30 [best])30 was administered according to pro-
tocol consistent with the Consortium for the Establishment
of a Registry for Alzheimer’s Disease battery.31,32
Processing Speed
The Wechsler Adult Intelligence Scale Revised Digit Sym-
bol Substitution Task was used to test complex visual
attention, sustained and focused concentration, response
speed, and visuomotor coordination, and the Trail-Making
Test Part A (TMT-A) was used to measure visual concep-
tual and visuomotor tracking, attention, sequencing, men-
tal flexibility, visual search, and motor function (nearest
0.01 seconds, maximum 4 minutes).32 Because slower
times indicate poorer performance, times were multiplied
by 1 for analyses so that higher numbers represented
better performance.
Memory
The Rey Auditory Verbal Learning Test (range 0–15)
assesses learning and memory using multiple learning trials
and a 30-minute delayed recall of 15 items on a list.32 The
Wechsler Adult Intelligence Scale III Incidental Learning
Task allows continuation of the Digit Symbol Substitution
Task until the third row of the test has been completed.33
After a 5-minute delay, the symbol pairs with free-recall32
are presented again.
Language
The FAS was used to measure letter fluency; participants
must spontaneously produce words beginning with a spe-
cific letter (F, A, S) within 60 seconds.32 The Animal Nam-
ing Task was used to measure category (animals) fluency.31
Executive Function
The TMT-B was used to assess attention, sequencing, men-
tal flexibility, visual search and motor function using time
and error counts.32 Times were multiplied by 1 so that
higher scores represented better function.
Composite Cognitive Domain Measures
Composite measures for processing speed, memory, and
language domains were constructed from two tests within
each domain to reduce measurement error and floor and
ceiling effects of individual tests.34–36 A standardized
z-score was created for each measure, and z-scores were
averaged within a domain to create the composite.34–36 A
factor-analytical combination method for constructing the
domain scores yielded similar associations between
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inflammation and cognitive measures (results available on
request).
Covariates
Blood pressure, measured three times in a seated, resting
state with appropriately sized cuffs, was defined as the
average of the second and third measurements. Hyperten-
sion was defined as measured blood pressure greater than
140/90, self-report of high blood pressure, or antihyper-
tensive medication use. Diabetes mellitus was defined as
fasting glucose of 126 mg/dL or greater, random glucose
of 200 mg/dL or greater, self-report of diabetes mellitus,
or hypoglycemic medication use. Antianxiety, antidepres-
sant, hypnotic, and narcotic medications and sleep aids
(over the counter or prescription) taken in the previous
2 weeks were classified as medications with potential to
affect cognition. Never-smoker was defined as having
never smoked more than 100 cigarettes. Height was mea-
sured using a stadiometer and weight using an electronic
balance with participants wearing lightweight clothes.
Body mass index (BMI) was calculated as weight (kg)/
height2 (m2).
Statistical Analysis
Associations between inflammatory markers and each cog-
nitive domain were estimated using linear models fit with
generalized estimating equations (GEEs) to account for
familial clustering and Huber-White robust standard error
estimates. Because inflammatory markers and cognitive
function scores all use different measurement units, stan-
dardized outcomes and predictors were modeled to facili-
tate comparison of models. Thus, a beta coefficient of 0.5
is interpreted as a 0.5–standard deviation (SD) decrease in
the cognitive score outcome being associated with a 1-SD
increase in the inflammatory marker. Diagnostic lowess
smoothers revealed linear relationships on the natural scale,
inflammatory markers were only mildly skewed, and esti-
mates were resistant to any extreme value effects (Fig-
ure 1), hence associations are presented with standardized,
non-log-transformed inflammatory markers. Primary
adjusted models included age, education, and sex and
accounted for familial clustering. Extended adjusted models
also included diabetes mellitus, hypertension, BMI, smok-
ing, stroke history, alcohol, lipid-lowering medications,
and central nervous system medications. Differences
according to race were examined using interaction terms,
acknowledging that race and site are aliased by design
(meaning that all AAs are from one site and all EAs from
another). Results are presented stratified according to race
as shorthand for AA (MS)/EA (MN) race (site) groups.
Characteristics of participants who had and who were
missing cognitive data were evaluated according to race,
and sensitivity analyses were conducted using weighted
GEEs to examine the robustness of findings after account-
ing for missing cognitive data. Analyses were performed
using STATA 12 (Stata Corp., College Station, TX).
Figure 1. Raw cognitive score means according to race-stratified soluble tumor necrosis factor receptor 2 inflammatory tertile.
Open squares indicate raw cognitive score means with individual raw cognitive scores displayed as points within each tertile.
MMSE = Mini-Mental State Examination; DSST = Digit Symbol Substitution Task; TMT-A = Trail-Making Test Part A;
RAVLT = Rey Auditory Verbal Learning Test; Incidental Learning—Wechsler Adult Intelligence Scale-III Incidental Learning
Task; TMT-B—Trail-Making Test Part B; T1 = Tertile 1; T2 = Tertile 2; T3 = Tertile 3.
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RESULTS
Characteristics are shown for participants with inflamma-
tory marker data, stratified according to race and presence
versus absence of cognitive data (Table 1). AAs were older
and more likely to be female, to have diabetes mellitus, to
have hypertension, to have ever smoked, to have a higher
BMI, and to have higher CRP and IL6 and lower sTNFR1
levels; and sTNFR2 levels were similar in AAs and EAs.
MMSE scores ranged from 14 to 30 (mean 27.9  2.3).
Fourteen AAs (2.0%) and eight EAs (1.1%) met race-
specific criteria for cognitive impairment.37
All cognitive data were missing in 271 (22%) EAs and
421 (32%) AAs. In EAs, missing data were associated with
being younger (P = .02) and male (P = .008) and having
diabetes mellitus (P = .04). AAs who were missing cogni-
tive data were more likely to have diabetes mellitus
(P = .003) and to have a higher BMI (P = .03), a lower
education level (P < .001), and higher levels of all inflam-
matory markers (sTNFR1, P = .005; sTNFR2, P = .006;
CRP, P = .01; and IL6, P = .006) than AAs with cognitive
data (Table 1).
Mean race-stratified cognitive scores according to
inflammatory tertiles differed in AAs and EAs (Figure 1).
For example, in AAs, all cognitive measures were worse
with increasing tertile of sTNFR2. In EAs, only processing
speed (P < .001) and executive function (P = .03) were
associated with sTNFR2 (Table 2, Figure 1). In AAs,
sTNFR1 was also associated with cognitive domains (all
P < .05), except for memory, whereas in EAs, processing
speed (P < .001), language (P = .011), executive function
(P < .001), and marginally memory (P = .097) were asso-
ciated with sTNFR1. CRP was associated with memory in
EAs (P = .04), but no associations were observed between
cognition and CRP or IL6 in AAs. IL6 was associated with
processing speed (P < .001), language (P < .002), and
executive function (P = .03) in EAs (Table 2, Figure 1).
In adjusted models, every 1-SD increase in sTNFR2
was associated with a 0.11-SD lower MMSE score in AA
(b = 0.11, 95% confidence interval (CI) = 0.20 to –
0.03, P = .009). The data did not support a similar associ-
ation in EAs (b = 0.03, 95% CI = 0.01–0.07, P = .14);
the interaction term supported a different relationship
according to race (b = 0.14, 95% CI = 0.24 to 0.05,
P = .003, Figure 2, Table 3). Similar to the MMSE out-
come, the data supported inverse associations between
sTNFR2 and all other cognitive domains for AAs but not
EAs. (Table 3, Figure S1) Each SD increase in sTNFR2 in
AAs was associated with poorer performance in processing
speed (b = 0.11, 95% CI = –0.16 to 0.07, P < .001),
language (b = 0.08, 95% CI = 0.13 to 0.03,
P = .002), memory (b = 0.0, 95% CI = 0.16 to 0.02,
P = .008), and executive function (b = 0.07, 95%
CI = 0.13 to 0.01, P = .03). The inferences were the
same in extended adjusted models (data available on
request).
Higher sTNFR1 in AAs was associated with slower
processing speed (b = 0.08, 95% CI = 0.12 to 0.04,
P < .001) and executive function in adjusted models
(Figure S1, Table 3: b = 0.08 95% CI = 0.14 to 0.02,
P = .008). The associations between sTNFR1 and MMSE
or language in AAs were similar in magnitude but did not
reach statistical significance (MMSE: b = 0.07, 95%
CI = 0.16–0.0, P = .09; language: b = 0.04, 95%
CI = 0.09–0.00, P = .07). In AAs, higher CRP was associ-
ated with slower processing speed (b = 0.04, 95%
Table 1. Participant Characteristics According to Race and Cognitive Data
Characteristic
European Americans African Americans
With Cognitive
Data, n = 960
Missing Cognitive
Data, n = 272
With Cognitive
Data, n = 1,005
Missing Cognitive
Data, n = 474
Age, mean  SD 59.2  10.0 57.6  10.9 62.9  8.7 63.3  10.9
Female, % 565 (59) 135 (50) 707 (70) 341 (72)
Body mass
index, kg/m2,
mean  SD
30.5  6.0 31.6  7.4 31.3  6.3 32.4  7.6
Hypertension, % 706 (74) 191 (70) 789 (79) 385 (81)
Diabetes mellitus, % 131 (14) 51 (19) 270 (27) 164 (35)
Never smoked, % 466 (49) 142 (52) 398 (40) 196 (41)
Education, %
<12 years 51  7 15  7 301  36 213  52
12 years 402  52 116  53 279  33 112  28
Some college 139  18 38  17 18  2 7  2
≥College degree 182  23 51  23 246  29 75  18
sTNFR1, pg/mL,
mean  SD
1,362  681 1,480  947 1,171  622 1,318  754
sTNFR2, pg/mL,
mean  SD
1,953  797 1,932  884 1,878  811 2,065  976
C-reactive protein,
SI, mean  SD
40.4  48.0 39.5  48.4 53.9  61.2 60.9  63.6
Interleukin 6, SI,
mean  SD
1.11  0.87 1.23  0.97 1.23  0.87 1.35  0.91
SD = standard deviation; sTNFR = soluble tumor necrosis factor receptor.
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CI = 0.070 to 0.010) P = .02), and higher IL6 was asso-
ciated with poorer executive function (b = 0.07, 95%
CI = 0.12 to 0.01, P = .02) (Table 3, Supplemental
Figure).
In EAs, sTNFR1 was associated only with processing
speed (b = 0.05, 95% CI = 0.08 to 0.01, P = .007);
sTNFR2, IL6, and CRP were not statistically associated
with any cognitive domain (Supplemental Figure, Table 3).
Sensitivity analyses using weighted GEEs suggested
that the reported results comparably or more conserva-
tively estimate associations between inflammatory markers
and cognitive function (Supplementary Table).
DISCUSSION
In a cohort of EAs and AAs with hypertension and their
siblings (with and without hypertension), substantial pro-
portions of whom had other risk factors for cardiovascular
disease, inflammatory markers were differently associated
with cognitive function in AAs and EAs. In AAs, a biomar-
ker of TNFa activity was associated with five domains of
cognitive function, whereas IL6 and CRP were associated
only with executive function and processing speed, respec-
tively; in EAs, only markers of TNFa activity were associ-
ated with a single cognitive domain, processing speed.
Although the cohort overall may be considered at high risk
of cardiovascular disease, cardiovascular risk factors were
also more prevalent in AAs than EAs. These findings sug-
gest that, in these young to old AAs with hypertension or
a strong family history of hypertension and prevalent
cardiovascular risk factors, TNFa activity, and perhaps
IL6 and CRP, may be important risk factors for cognitive
dysfunction.T
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Figure 2. Differential associations between soluble tumor
necrosis factor receptor 2 (sTNFR2) and Mini-Mental State
Examination (MMSE) score in African Americans (AAs: dark
gray) and European Americans (EAs: light gray) from
adjusted models. Solid lines are regression lines with shaded
confidence bounds. Dashed lines are LOWESS nonlinear
smoothers (diagnostic check). Race specific standard devia-
tions (SDs) and standardized beta coefficients are shown with
subscripted lower and upper 95% confidence limits (lower
confidence limit “LCL” and upper confidence limit “UCL”),
displayed as LCLbUCL.
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One explanation for these findings in this population
could involve inflammatory-mediated cerebrovascular dis-
ease. Cardiovascular risk factors, inflammation,5,7,13,38,39
brain structure abnormalities,40 and poor cognitive func-
tion,41,42 particularly executive function41 and processing
speed,41 are interrelated. Mechanisms linking blood pres-
sure to cognition are especially relevant for this study popu-
lation and have been classified as functional (e.g.,
endothelial dysfunction or vascular dysregulation; altered
blood flow, including nocturnal dipping patterns; reduced
amyloid clearance), structural (e.g., white matter hyperin-
tensities, atrophy), pharmacological (related to renin-angio-
tensin system), stroke related, and other (including
hypertension with insulin resistance or impaired insulin sig-
naling centrally).43 AAs are disproportionately burdened by
cardiovascular disease44 and may exhibit heightened
responses and greater endothelial dysfunction in response to
inflammatory stimuli in vasculature, specifically TNFa path-
ways.23 Furthermore, TNFa upregulation has been observed
in individuals with hypertension,45 and more than 70% of
this cohort was hypertensive, whereas the remainder had at
least two siblings with hypertension before age 60. Thus,
inflammation may mediate cognitive decline through arte-
riosclerotic disease in the brain but may also adversely affect
cognition through direct effects of inflammation on synaptic
plasticity, neurogenesis, and neuromodulation that affect
cognition.46 High inflammatory biomarker levels can occur
for a number of reasons, and mechanisms explaining the
link between inflammation and cognition in this cross-
sectional cohort study could not be elucidated, although
these findings can be considered hypothesis generating in a
sample of AAs most of whom had hypertension.
These findings further complement and expand upon
those of other studies linking inflammation and cogni-
tion4,6–10,13–18,47 by reporting findings from a relatively
large AA cohort across a broad age range. Studies in older
adults demonstrate associations between higher TNFa
activity and poorer cognitive function,10 higher TNFa
activity in individuals with VaD than in those with AD,18
and higher TNFa activity in individuals with VaD or AD
than in controls.18,48 In this cognitively unimpaired cohort
aged 28 to 91, associations were found between inflamma-
tion and poor cognitive function in AAs. A longitudinal
Swedish study that showed higher baseline sTNFR1 and
sTNFR2 levels in persons with mild cognitive impairment
who converted to dementia than in those with mild cogni-
tive impairment who remained stable or in controls
supported these findings.12 A relationship between TNFa
and executive function decline, but not other cognitive
domains, was observed in the largely EA Framingham
Offspring cohort.10 Associations were observed with pro-
cessing speed only in the GENOA EA. Differences in the
cohorts’ prevalent cardiovascular risk factors, with the
GENOA cohort having a greater burden, might explain
some of the inconsistency. In addition, the current analysis
was cross-sectional, and the Framingham Offspring study
was longitudinal.
The Framingham Offspring and GENOA cohorts were
younger than many participants in studies of inflammation
and cognition. Findings in these younger cohorts are of par-
ticular interest because interventions to halt or delay cogni-
tive decline may be more effective in earlier stages. It wouldT
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also be of interest to see whether interventions that target
the conditions that cause inflammation are more successful
than interventions that target existing inflammation.
Although the individual estimates of associations
between standardized inflammatory biomarkers and stan-
dardized cognitive measures may appear small, going from
lowest to highest sTNFR2 values, there was an average
2-point difference in MMSE score, which is clinically
meaningful. To put the sTNFR2 effect further into con-
text, an increase in 1 SD of sTNFR2 (b = 0.11) would
be similar to a 5-year difference in age (age b = 0.02 per
year); across the range of sTNFR2 from 252 to 2,690 lg,
this would be similar to 20 years of aging.
Some limitations warrant further discussion. The dif-
ferent results according to race could be due to regional
differences in the AA and EA populations, because study
sites were race specific. Regardless, the relationships are of
interest. In addition to potential race and site effects, the
higher risk profile in AAs (e.g., older age; more obesity,
hypertension, diabetes mellitus) could contribute to differ-
ential findings. This explanation is of particular interest
because it might identify mechanisms that are more rele-
vant in populations with prevalent cardiovascular risk fac-
tors. In addition, this study was limited to four
inflammatory markers (CRP, sTNFR1 and 2, and IL6),
even though other proinflammatory markers have been
found to be associated with cognition, including other ILs
and serum amyloid A.49,50 Nevertheless, the biomarkers in
the current study are among those with biological plausi-
bility and some evidence in other studies, although mostly
in EAs, that they are important in vascular and nonvascu-
lar cognitive impairment. Numerous triggers can cause
inflammatory biomarkers to be high, and the influence of
other conditions that increase inflammation could not be
excluded, although the results remained significant even
after accounting for several comorbidities associated with
inflammation, including cardiovascular disease and diabe-
tes mellitus. In addition to adjusting for other potential
confounders in parsimonious and extended adjusted mod-
els, standard approaches of stratification were included,
and sensitivity analyses were conducted for potential infor-
mative missingness effects. Although the cognitive mea-
sures may not detect early decline, significant relationships
were observed in this population. Additional limitations
include the cross-sectional design, which limits inferences
of causality. Volunteer bias may limit generalizability to
dissimilar populations, but the findings reported are among
a few reporting such relationships in AAs. Longitudinal
studies could address some limitations by assessing tempo-
ral associations between inflammation and cognitive
decline.
CONCLUSION
Inflammation is increasingly recognized as an important
contributor to numerous health outcomes. Deleterious
effects on cognitive function may be especially apparent in
AAs with vascular risk factors. The associations between
inflammation and cognitive function across a broad age
spectrum in cognitively unimpaired AAs with vascular risk
factors require further study to ascertain pathways through
which inflammation, specifically TNFa activity, may erode
cognitive function. In addition, studies targeting modifiable
vascular risk factors and effects on inflammation and cog-
nitive function in at-risk populations are needed.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Associations Between standardized inflam-
matory markers and cognitive domains, adjusted for age,
sex, and education and accounting for familial clustering.
Regression coefficients with lower and upper confidence
limits are shown. Black lines indicate statistically signifi-
cant results. sTNFR, soluble tumor necrosis factor recep-
tor; CRP, high sensitivity C-reactive protein; IL6,
interleukin 6; MMSE, Mini-Mental State Examination; PS,
Processing Speed; executive function, Executive Function.
Tables S1. Relationships Between Cognitive Domains
and Inflammatory Markers in European and African
Americans. Sensitivity to Missing Cognitive Outcomes
Comparing Generalized Estimating Equations (GEE) and
Weighted GEE (wGEE).
Please note: Wiley-Blackwell is not responsible for the
content, accuracy, errors, or functionality of any support-
ing materials supplied by the authors. Any queries (other
than missing material) should be directed to the corre-
sponding author for the article.
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